Vancouver BC-based
Emerald Health Therapeutics Inc. (CSE: EMH, OTCMKTS: EMHTF, Forum) announced this week that it had entered into a license agreement with
FlowerPod LLC, a private US company.
Emerald Health is providing FP with the exclusive use of patented technology for developing and marketing cannabis-related products for use in all US states where adult use and/or medical cannabis is legal.
The initial prototype product designed by Emerald, utilizing its Defined Dose expertise, has been refined over the last 15 months through a collaboration between FP and Emerald.
About 50% of cannabis consumers are largely influenced by the convenience of the consumption form when choosing a cannabis product, qualifying it as a top-5 influencer.
This soon-to-launch specialty product targets cannabis flower users and is expected to provide a more convenient method of consuming whole spectrum dried flower cannabis and ensure a consistent amount of active ingredient with every use of the product. This is expected to provide users with greater predictability and control of their cannabis consumption.
For the full story, click
here.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub on Stockhouse.
FULL DISCLOSURE: Emerald Health Therapeutics Inc. is a client of Stockhouse Publishing.